Report Tools

Pharmaceuticals - BRIC (Brazil, Russia, India, China) Industry Guide

Published: November 2012 · Publisher: MarketLine
Pharmaceuticals - BRIC (Brazil, Russia, India, China) Industry Guide is an essential resource for top-level data and analysis covering the BRIC (Brazil, Russia, India, China) Pharmaceuticals industry. The report includes easily comparable data on ...
Report Type Industry Guides
Language English
Format Electronic (PDF)
Pages116
Frequency Updated Annually
Availability Will be emailed within 1 business day
Reference No. 0109-1046
Price € 749,00
Options
  • Description
  • Table of Contents
  • Ask a Question
Pharmaceuticals - BRIC (Brazil, Russia, India, China) Industry Guide is an essential resource for top-level data and analysis covering the BRIC (Brazil, Russia, India, China) Pharmaceuticals industry. The report includes easily comparable data on market value, volume, segmentation and market share, plus full five year market forecasts. It examines future problems, innovations and potential growth areas within the market.

Scope of the Report

* Contains an executive summary and data on value, volume and segmentation

* Provides textual analysis of the industry's prospects, competitive landscape and profiles of the leading companies

* Incorporates in-depth five forces competitive environment analysis and scorecards

* Compares data from Brazil, Russia, India, and China, alongside individual chapters on each country. .

* Includes a five-year forecast of the industry

Highlights

Brazil, Russian Federation, India and China (BRIC) are the emerging and fast growing countries within the pharmaceuticals industry and had a total market value of $101.8 billion in 2011. China was the fastest growing country with a CAGR of 20.6% over the 2007-11 period.

Within the pharmaceuticals industry, China is the leading country among the BRIC nations with market revenues of $55.4 billion in 2011.

China is expected to lead the pharmaceuticals industry in the BRIC nations with a value of $108.1 billion in 2016, followed by Brazil, India, Russia with expected values of $29.0, $27.3 and $24.9 billion, respectively.



Why you should buy this report

* Spot future trends and developments

* Inform your business decisions

* Add weight to presentations and marketing materials

* Save time carrying out entry-level research

Market Definition

The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare.
Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors).
Any currency conversions used in the production of this report have been calculated at constant 2011 annual average exchange rates.
Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.
TABLE OF CONTENTS
Introduction 10
What is this report about? 10
Who is the target reader? 10
How to use this report 10
Definitions 10
BRIC Pharmaceuticals Industry Outlook 11
Pharmaceuticals in Brazil 15
Market Overview 15
Market Data 16
Market Segmentation 17
Market outlook 19
Five forces analysis 20
Leading companies 28
Macroeconomic indicators 34
Pharmaceuticals in China 36
Market Overview 36
Market Data 37
Market Segmentation 38
Market outlook 40
Five forces analysis 41
Leading companies 49
Macroeconomic indicators 57
Pharmaceuticals in India 59
Market Overview 59
Market Data 60
Market Segmentation 61
Market outlook 63
Five forces analysis 64
Leading companies 72
Macroeconomic indicators 85
Pharmaceuticals in Russia 87
Market Overview 87
Market Data 88
Market Segmentation 89
Market outlook 91
Five forces analysis 92
Leading companies 100
Macroeconomic indicators 113
Appendix 115
Methodology 115

LIST OF TABLES
Table 1: BRIC pharmaceuticals industry, revenue($bn), 2007-16 11
Table 2: BRIC pharmaceuticals industry, revenue($bn), 2007-11 13
Table 3: BRIC pharmaceuticals industry, revenue($bn), 2007-11 14
Table 4: Brazil pharmaceuticals market value: $ billion, 2007–11 16
Table 5: Brazil pharmaceuticals market geography segmentation: $ billion, 2011 17
Table 6: Brazil pharmaceuticals market share: % share, by value, 2011 18
Table 7: Brazil pharmaceuticals market value forecast: $ billion, 2011–16 19
Table 8: Aché Laboratórios Farmaceuticos S.A.: key facts 28
Table 9: Medley Indústria Farmaceutica Ltd: key facts 29
Table 10: Sanofi: key facts 30
Table 11: Sanofi: key financials ($) 31
Table 12: Sanofi: key financials (€) 31
Table 13: Sanofi: key financial ratios 31
Table 14: EMS Sigma Pharma: key facts 33
Table 15: Brazil size of population (million), 2007–11 34
Table 16: Brazil gdp (constant 2000 prices, $ billion), 2007–11 34
Table 17: Brazil gdp (current prices, $ billion), 2007–11 34
Table 18: Brazil inflation, 2007–11 35
Table 19: Brazil consumer price index (absolute), 2007–11 35
Table 20: Brazil exchange rate, 2007–11 35
Table 21: China pharmaceuticals market value: $ billion, 2007–11 37
Table 22: China pharmaceuticals market geography segmentation: $ billion, 2011 38
Table 23: China pharmaceuticals market share: % share, by value, 2011 39
Table 24: China pharmaceuticals market value forecast: $ billion, 2011–16 40
Table 25: Pfizer Inc.: key facts 49
Table 26: Pfizer Inc.: key financials ($) 50
Table 27: Pfizer Inc.: key financial ratios 50
Table 28: AstraZeneca PLC: key facts 52
Table 29: AstraZeneca PLC: key financials ($) 53
Table 30: AstraZeneca PLC: key financial ratios 54
Table 31: Jiangsu Yangtze River Pharmaceutical Group Company Ltd.: key facts 56
Table 32: China size of population (million), 2007–11 57
Table 33: China gdp (constant 2000 prices, $ billion), 2007–11 57
Table 34: China gdp (current prices, $ billion), 2007–11 57
Table 35: China inflation, 2007–11 58
Table 36: China consumer price index (absolute), 2007–11 58
Table 37: China exchange rate, 2007–11 58
Table 38: India pharmaceuticals market value: $ billion, 2007–11 60
Table 39: India pharmaceuticals market geography segmentation: $ billion, 2011 61
Table 40: India pharmaceuticals market share: % share, by value, 2011 62
Table 41: India pharmaceuticals market value forecast: $ billion, 2011–16 63
Table 42: Dr. Reddy's Laboratories Limited: key facts 72
Table 43: Dr. Reddy's Laboratories Limited: key financials ($) 73
Table 44: Dr. Reddy's Laboratories Limited: key financials (Rs.) 73
Table 45: Dr. Reddy's Laboratories Limited: key financial ratios 73
Table 46: Cipla Limited: key facts 75
Table 47: Cipla Limited: key financials ($) 76
Table 48: Cipla Limited: key financials (Rs.) 76
Table 49: Cipla Limited: key financial ratios 76
Table 50: Ranbaxy Laboratories Limited: key facts 78
Table 51: Ranbaxy Laboratories Limited: key financials ($) 79
Table 52: Ranbaxy Laboratories Limited: key financials (Rs.) 79
Table 53: Ranbaxy Laboratories Limited: key financial ratios 79
Table 54: Lupin Limited: key facts 81
Table 55: Lupin Limited: key financials ($) 82
Table 56: Lupin Limited: key financials (Rs.) 82
Table 57: Lupin Limited: key financial ratios 83
Table 58: India size of population (million), 2007–11 85
Table 59: India gdp (constant 2000 prices, $ billion), 2007–11 85
Table 60: India gdp (current prices, $ billion), 2007–11 85
Table 61: India inflation, 2007–11 86
Table 62: India consumer price index (absolute), 2007–11 86
Table 63: India exchange rate, 2007–11 86
Table 64: Russia pharmaceuticals market value: $ billion, 2007–11 88
Table 65: Russia pharmaceuticals market geography segmentation: $ billion, 2011 89
Table 66: Russia pharmaceuticals market share: % share, by value, 2011 90
Table 67: Russia pharmaceuticals market value forecast: $ billion, 2011–16 91
Table 68: Pharmstandard OJSC: key facts 100
Table 69: Pharmstandard OJSC: key financials ($) 100
Table 70: Pharmstandard OJSC: key financials (RUB) 101
Table 71: Pharmstandard OJSC: key financial ratios 101
Table 72: Sanofi: key facts 103
Table 73: Sanofi: key financials ($) 104
Table 74: Sanofi: key financials (€) 104
Table 75: Sanofi: key financial ratios 104
Table 76: Novartis AG: key facts 106
Table 77: Novartis AG: key financials ($) 107
Table 78: Novartis AG: key financial ratios 107
Table 79: Bayer AG: key facts 109
Table 80: Bayer AG: key financials ($) 110
Table 81: Bayer AG: key financials (€) 110
Table 82: Bayer AG: key financial ratios 111
Table 83: Russia size of population (million), 2007–11 113
Table 84: Russia gdp (constant 2000 prices, $ billion), 2007–11 113
Table 85: Russia gdp (current prices, $ billion), 2007–11 113
Table 86: Russia inflation, 2007–11 114
Table 87: Russia consumer price index (absolute), 2007–11 114
Table 88: Russia exchange rate, 2007–11 114

LIST OF FIGURES
Figure 1: BRIC pharmaceuticals industry, revenue($bn), 2007-16 11
Figure 2: BRIC pharmaceuticals industry, revenue($bn), 2007-11 13
Figure 3: BRIC pharmaceuticals industry, revenue($bn), 2007-11 14
Figure 4: Brazil pharmaceuticals market value: $ billion, 2007–11 16
Figure 5: Brazil pharmaceuticals market geography segmentation: % share, by value, 2011 17
Figure 6: Brazil pharmaceuticals market share: % share, by value, 2011 18
Figure 7: Brazil pharmaceuticals market value forecast: $ billion, 2011–16 19
Figure 8: Forces driving competition in the pharmaceuticals market in Brazil, 2011 20
Figure 9: Drivers of buyer power in the pharmaceuticals market in Brazil, 2011 21
Figure 10: Drivers of supplier power in the pharmaceuticals market in Brazil, 2011 23
Figure 11: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Brazil, 2011 24
Figure 12: Factors influencing the threat of substitutes in the pharmaceuticals market in Brazil, 2011 26
Figure 13: Drivers of degree of rivalry in the pharmaceuticals market in Brazil, 2011 27
Figure 14: Sanofi: revenues & profitability 32
Figure 15: Sanofi: assets & liabilities 32
Figure 16: China pharmaceuticals market value: $ billion, 2007–11 37
Figure 17: China pharmaceuticals market geography segmentation: % share, by value, 2011 38
Figure 18: China pharmaceuticals market share: % share, by value, 2011 39
Figure 19: China pharmaceuticals market value forecast: $ billion, 2011–16 40
Figure 20: Forces driving competition in the pharmaceuticals market in China, 2011 41
Figure 21: Drivers of buyer power in the pharmaceuticals market in China, 2011 42
Figure 22: Drivers of supplier power in the pharmaceuticals market in China, 2011 44
Figure 23: Factors influencing the likelihood of new entrants in the pharmaceuticals market in China, 2011 45
Figure 24: Factors influencing the threat of substitutes in the pharmaceuticals market in China, 2011 47
Figure 25: Drivers of degree of rivalry in the pharmaceuticals market in China, 2011 48
Figure 26: Pfizer Inc.: revenues & profitability 51
Figure 27: Pfizer Inc.: assets & liabilities 51
Figure 28: AstraZeneca PLC: revenues & profitability 54
Figure 29: AstraZeneca PLC: assets & liabilities 55
Figure 30: India pharmaceuticals market value: $ billion, 2007–11 60
Figure 31: India pharmaceuticals market geography segmentation: % share, by value, 2011 61
Figure 32: India pharmaceuticals market share: % share, by value, 2011 62
Figure 33: India pharmaceuticals market value forecast: $ billion, 2011–16 63
Figure 34: Forces driving competition in the pharmaceuticals market in India, 2011 64
Figure 35: Drivers of buyer power in the pharmaceuticals market in India, 2011 65
Figure 36: Drivers of supplier power in the pharmaceuticals market in India, 2011 67
Figure 37: Factors influencing the likelihood of new entrants in the pharmaceuticals market in India, 2011 68
Figure 38: Factors influencing the threat of substitutes in the pharmaceuticals market in India, 2011 70
Figure 39: Drivers of degree of rivalry in the pharmaceuticals market in India, 2011 71
Figure 40: Dr. Reddy's Laboratories Limited: revenues & profitability 74
Figure 41: Dr. Reddy's Laboratories Limited: assets & liabilities 74
Figure 42: Cipla Limited: revenues & profitability 77
Figure 43: Cipla Limited: assets & liabilities 77
Figure 44: Ranbaxy Laboratories Limited: revenues & profitability 80
Figure 45: Ranbaxy Laboratories Limited: assets & liabilities 80
Figure 46: Lupin Limited: revenues & profitability 83
Figure 47: Lupin Limited: assets & liabilities 84
Figure 48: Russia pharmaceuticals market value: $ billion, 2007–11 88
Figure 49: Russia pharmaceuticals market geography segmentation: % share, by value, 2011 89
Figure 50: Russia pharmaceuticals market share: % share, by value, 2011 90
Figure 51: Russia pharmaceuticals market value forecast: $ billion, 2011–16 91
Figure 52: Forces driving competition in the pharmaceuticals market in Russia, 2011 92
Figure 53: Drivers of buyer power in the pharmaceuticals market in Russia, 2011 93
Figure 54: Drivers of supplier power in the pharmaceuticals market in Russia, 2011 95
Figure 55: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Russia, 2011 96
Figure 56: Factors influencing the threat of substitutes in the pharmaceuticals market in Russia, 2011 98
Figure 57: Drivers of degree of rivalry in the pharmaceuticals market in Russia, 2011 99
Figure 58: Pharmstandard OJSC: revenues & profitability 101
Figure 59: Pharmstandard OJSC: assets & liabilities 102
Figure 60: Sanofi: revenues & profitability 105
Figure 61: Sanofi: assets & liabilities 105
Figure 62: Novartis AG: revenues & profitability 108
Figure 63: Novartis AG: assets & liabilities 108
Figure 64: Bayer AG: revenues & profitability 111
Figure 65: Bayer AG: assets & liabilities 112


Copyright © FriedlNet. You may share using our tools Please don't cut content from FriedlNet and redistribute by email or post to the web.